Determination of Nilotinib in Spiked Plasma, Urine, and Capsules by High-Performance Liquid Chromatography with Fluorimetric Detection

Yilmaz E. M., Aydogmus Z., Aboul-Enein H. Y.

ACTA CHROMATOGRAPHICA, vol.28, no.3, pp.313-331, 2016 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1556/1326.2016.28.3.3
  • Journal Name: ACTA CHROMATOGRAPHICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.313-331
  • Keywords: nilotinib, 4-chloro-7-nitrobenzofurazan, HPLC, plasma, urine, pharmaceutical analysis, stability studies, TANDEM MASS-SPECTROMETRY, TYROSINE KINASE INHIBITORS, IMATINIB, DASATINIB, QUANTIFICATION, SORAFENIB, LAPATINIB, SUNITINIB, ERLOTINIB, AMN107
  • Istanbul University Affiliated: Yes

Abstract

A precise and sensitive reversed phase high-performance thin-layer chromatography (RP-HPLC) method was developed for the determination of nilotinib (NTB) in spiked plasma, urine, and pharmaceutical capsule formulation. The method was based on derivatization NTB with 4-chloro-7-nitrobenzofurazan (NBD-Cl) in the borax buffer (pH 9). The method employs an isocratic elution using acetonitrile and 10 mM orthophosphoric acid (40: 60 v/v) as a mobile phase and an C-18 column (4.6 mm x 250 mm, 5 mu m, Waters Symmetry), with a fluorescence detector (lambda(ex): 447 nm, lambda(em): 530 nm). The method validation was performed with respect to linearity, recovery, accuracy, precision, and stability. The linear ranges were 100-600 ng mL(-1) in standard solution, plasma, and urine. Correlation coefficients (r(2)) were higher than 0.9997 for all of the analytes, indicating good linear relationship. The percentage recovery was 87.89% for plasma, 95.35% for urine, and 96.07% for capsules.